- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02839226
Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds
July 19, 2016 updated by: Arava Bio Tech Ltd.
Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients
This prospective, placebo-controlled, double blind, randomized study is designed to assess the healing effects of AR/101 on chronic Hard-to-Heal wound(s) of different etiologies including arterial ulcers, diabetic ulcers and venous ulcers, of at least 3 months duration.
After collection of comprehensive medical data to confirm eligibility of patient and obtaining informed consent , patients will enter Screening run-in Period where all wounds will be cleaned if necessary by surgical debridement and irrigation (isotonic solution) prior to initiation (run-in phase) of the study according to physician's instructions.
During the 14 day screening period, all subjects will receive standard of care (SoC) on a daily basis, as per indication and patients status, according to physicians instructions.
Wounds will be morphologically assessed by the treating physician and by photographic evaluation by the PI once a week - at days 7 and 14 of the screening run-in phase.
Following the run-in period, Subjects with wounds of ≥ 5cm2 and ≤100 cm2 of at least 3 months duration that fail to respond to treatment with SoC during the screening run-in phase will be enrolled into the study.
Eligible subjects with wounds will be randomized and treated topically with AR/101+ SoC or placebo +SoC once daily for up to 14 days.
During this treatment phase I, depending on their wound size and wound type, subjects will receive treatment dose applied topically daily and wounds will be dressed according to physician's instructions.
Wounds will be photographed daily and assessed by the treating physician in the clinic once a week (at the end of each weekly period).
During the treatment period, adverse events and concomitant medications will be monitored; wounds will be morphologically assessed by photo documentation and followed for wound bed progression and granulation tissue formation.
At the end of Treatment period I, patient's wounds will be analyzed and all patients from both treatment arms with wound score 0-2 will be assigned to receive the study drug for and additional up to 14 days treatment phase II in full accordance with the treatment regimen described in Treatment phase I.
A termination visit will be performed at day 14 of Treatment phase I or II or earlier if the wound has reached the maximum score on the granulation scale or if the wound is ready for skin grafting; or in any case of early withdrawal that is not due to withdrawal of consent.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tamar Tennenbaum, MD
- Email: tamar@arava-bio.com
Study Contact Backup
- Name: Adi Dagan
- Email: adi@arava-bio.com
Study Locations
-
-
-
Tel Aviv, Israel, 96105
- Sourasky Medical Center
-
Contact:
- Eyal Gur, MD
- Email: Gur@tlvmc.gov.il
-
Contact:
- Meirav Sela, MSc
- Email: meiravs@tlvmc.gov.il
-
Principal Investigator:
- Eyal Gur, MD
-
Sub-Investigator:
- Eran Otremsky, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is 18 years old and above
- Have single/multiple wounds
- Have a chronic hard to heal wound of various etiologies for at least 3 months of duration
- Patient was treated for 14 days with SoC (screening run-in) and did not respond to treatment. "Response" is defined as formation of more than 10% of viable granulation tissue.
- Wound area is larger than 5cm2 and smaller than 100 cm2.
- Subject should be available for the entire study period, and be able and willing to adhere to protocol requirements
- Subject must sign an informed consent form prior to undergoing any study- related procedures.
- For female subjects only, the subject is either:
A. Surgically sterile B. At least 1 year post-menopausal.
C. Subject has consented to using one of the following acceptable methods of birth control for the times specified below:
- Intra-uterine device (IUD) in place for at least 3 months prior to screening visit and through study completion.
- Barrier method (condom or diaphragm) for at least 14 days prior to screening through study completion.
- Spermicide for at least 14 days prior to screening through study completion.
- Stable hormonal contraceptive for at least 3 months prior to screening visit through study completion.
- Surgical Sterilization (vasectomy) of partner at least 6 months prior to screening visit through study completion.
Exclusion Criteria:
- Have a documented medical history of a significant hematological, cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), or hepatic disease which per the physician's discretion prohibit them from entering the study.
- Had any clinically significant illness per the physician's discretion during the last 4 weeks prior to the screening period.
- Have a documented medical history . of HBV, HCV, HIV.
- Severely immunosuppressed for any reason that would limit or preclude healing in the opinion of the Investigator.
- Patient is currently receiving, or has received at any time within one month prior to enrollment, any medications or treatments known to affect the wound healing processes including Glucocorticosteroid treatment (Prednisone > 10mg/day or its equivalent), immuno-suppressive drugs, radiation therapy and chemotherapy.
- Use of growth factors, allogeneic skin grafts/ skin graft products within one month prior to enrollment.
- Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 1 year and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a blood-based pregnancy test.
- Clinically significant blood and urinalysis tests per the physician's discretion.
- Have any acute signs of infection in the wound, which could be linked to raised body temperature, abscess, necrosis, cellulitis or acute osteomyelitis.
- Have sinus tracts or tunnels, purulent discharge , gangrene or severe drainage that will cause skin maceration per the physician's discretion.
- Had any antibiotic treatment for acute infection during the screening period (prophylactic antibiotic treatment is allowed)
- Intolerance to compression therapy if required for venous ulcers or inability to follow SoC according to the physician's instructions.
- Had revascularization surgery during the past 3 months or be a candidate for revascularization surgery during the course of the study.
- Active wound care therapies within the past 3 months (e.g., manufactured dermis, full-thickness skin, Becaplermin, split thickness autologous skin grafts at the site of the target wound)
- Patients with poor nutritional status (albumin < 2.5g/dl), poor diabetic control (HbA1c > 12%), anemia (hemoglobin<8 g/dL), a leukocyte counts < 4,000// μl or >15000/μl, renal failure (Cr > 3 mg/dl);
- Active deep venous thrombosis (DVT)
- Patients with uncontrollable edema >+2
- Patients who in the opinion of the investigator, for any reason other than those listed above will not be able to complete the study per protocol.
- Participation in another clinical trial within 30 days prior to the Screening period or during this study.
History of mental illness that would preclude completion of the study
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AR/101
AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician.
After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
|
|
Placebo Comparator: Placebo
placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician.
After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients ready for skin grafting or healing by secondary intention during treatment phase 1 and treatment phase 2 based on physician's assessment
Time Frame: 28 days
|
28 days
|
Percent of patient responders of equal or more then 75% granulation tissue during two weeks of treatment phase 1
Time Frame: 14 days
|
14 days
|
Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 1
Time Frame: 14 days
|
14 days
|
Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2
Time Frame: 14 days
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
July 18, 2016
First Submitted That Met QC Criteria
July 19, 2016
First Posted (Estimate)
July 20, 2016
Study Record Updates
Last Update Posted (Estimate)
July 20, 2016
Last Update Submitted That Met QC Criteria
July 19, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR-H2H-2016-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds
-
Centre Hospitalier Universitaire de NīmesCompleted
-
University of WashingtonU.S. Department of Justice; Arnold Ventures; City of SeattleCompleted
-
3MWithdrawn
-
University of PittsburghThe Pittsburgh Foundation; Hillman Foundation; RK Mellon FoundationCompletedSkin Injury Due to Violence | Gunshot Wound, ContactUnited States
-
SerenaGroup, Inc.Anacapa Technologies IncCompleted
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
-
Smith & Nephew, Inc.Not yet recruitingChronic Wounds | Acute WoundsCanada
-
SerenaGroup, Inc.MDM Wound Ventures, LLCCompletedChronic Wounds | Acute WoundsUnited States
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Ohio State UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States